fexofenadine has been researched along with Disease Models, Animal in 13 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Allergic rhinitis is an inflammatory disease of the nasal mucosa, induced by histamine, leukotrienes, and other substances released from mast cells." | 5.33 | Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis. ( Makita, S; Sakairi, T; Shakuto, S; Suzuki, K; Wajima, T; Yaguchi, M; Yoshida, Y, 2005) |
| "Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments." | 5.31 | Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. ( Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002) |
| "Nasal obstruction is one of the most bothersome symptoms of allergic rhinitis (AR) affecting sleep-related quality of life in AR patients." | 1.56 | Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis. ( Aoyagi, H; Hirasawa, N; Kajiwara, D; Miyoshi, K; Tanaka, K; Tsunekuni, K, 2020) |
| "Olopatadine hydrochloride (olopatadine) is an antiallergic agent with histamine H(1) receptor antagonistic action." | 1.35 | Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. ( Kimoto, N; Tamura, T, 2009) |
| "Allergic rhinitis is an inflammatory disease of the nasal mucosa, induced by histamine, leukotrienes, and other substances released from mast cells." | 1.33 | Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis. ( Makita, S; Sakairi, T; Shakuto, S; Suzuki, K; Wajima, T; Yaguchi, M; Yoshida, Y, 2005) |
| "Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments." | 1.31 | Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. ( Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Odan, M | 1 |
| Ishizuka, N | 1 |
| Hiramatsu, Y | 1 |
| Inagaki, M | 1 |
| Hashizume, H | 1 |
| Fujii, Y | 1 |
| Mitsumori, S | 1 |
| Morioka, Y | 1 |
| Soga, M | 1 |
| Deguchi, M | 1 |
| Yasui, K | 1 |
| Arimura, A | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zhao, X | 1 |
| Liu, R | 1 |
| Chen, Y | 1 |
| Hettinghouse, A | 1 |
| Liu, C | 1 |
| Aoyagi, H | 1 |
| Kajiwara, D | 1 |
| Tsunekuni, K | 1 |
| Tanaka, K | 1 |
| Miyoshi, K | 1 |
| Hirasawa, N | 1 |
| Matsubara, R | 1 |
| Kumagai, K | 1 |
| Shigematsu, H | 1 |
| Kitaura, K | 1 |
| Nakasone, Y | 1 |
| Suzuki, S | 1 |
| Hamada, Y | 1 |
| Suzuki, R | 1 |
| Raveendran, VV | 1 |
| Kassel, KM | 1 |
| Smith, DD | 1 |
| Luyendyk, JP | 1 |
| Williams, KJ | 1 |
| Cherian, R | 1 |
| Reed, GA | 1 |
| Flynn, CA | 1 |
| Csanaky, IL | 1 |
| Lickteig, AL | 1 |
| Pratt-Hyatt, MJ | 1 |
| Klaassen, CD | 1 |
| Dileepan, KN | 1 |
| Akiyama, K | 1 |
| Karaki, M | 1 |
| Kobayshi, R | 1 |
| Dobashi, H | 1 |
| Ishida, T | 1 |
| Mori, N | 1 |
| Tamura, T | 1 |
| Kimoto, N | 1 |
| Gelfand, EW | 2 |
| Cui, ZH | 2 |
| Takeda, K | 2 |
| Kanehiro, A | 2 |
| Joetham, A | 2 |
| Sakairi, T | 1 |
| Suzuki, K | 1 |
| Makita, S | 1 |
| Wajima, T | 1 |
| Shakuto, S | 1 |
| Yoshida, Y | 1 |
| Yaguchi, M | 1 |
13 other studies available for fexofenadine and Disease Models, Animal
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
Topics: Administration, Oral; Animals; Antipruritics; CHO Cells; Cricetinae; Disease Models, Animal; Inhibit | 2012 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Cytosolic Phospholipase A2 Is Required for Fexofenadine's Therapeutic Effects against Inflammatory Bowel Disease in Mice.
Topics: Animals; Biomarkers, Pharmacological; Disease Models, Animal; Inflammatory Bowel Diseases; Mice; Mic | 2021 |
Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis.
Topics: Acetates; Animals; Anti-Allergic Agents; Cell Line; Cyclopropanes; Disease Models, Animal; Drug Syne | 2020 |
Fexofenadine Suppresses Delayed-Type Hypersensitivity in the Murine Model of Palladium Allergy.
Topics: Allergens; Animals; Anti-Allergic Agents; Antigen-Presenting Cells; Biomarkers; Cytokines; Disease M | 2017 |
H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice.
Topics: Animals; Apolipoproteins E; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Ca | 2014 |
IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model.
Topics: Animals; Anti-Allergic Agents; Carbazoles; Disease Models, Animal; Eosinophils; Female; Immunoglobul | 2009 |
Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.
Topics: Administration, Intranasal; Animals; Anti-Allergic Agents; Dibenzoxepins; Disease Models, Animal; Dr | 2009 |
Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness.
Topics: Adoptive Transfer; Allergens; Animals; Anti-Allergic Agents; Bronchial Hyperreactivity; Bronchoalveo | 2002 |
Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness.
Topics: Administration, Inhalation; Adoptive Transfer; Allergens; Animals; Anti-Allergic Agents; Antibody Sp | 2003 |
Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis.
Topics: Airway Resistance; Animals; Anti-Allergic Agents; Area Under Curve; Carbazoles; Disease Models, Anim | 2005 |